Geyser Brands Inc. (formerly Kanzen Capital Corp.) (TSXV:GYSR) (“Geyser Brands”or the “Company) is very pleased to announce the receipt of their Natural Product Number (NPN) from Health Canada for their hemp-based pain relief roll-on. Through the issuance of the NPN, Geyser Brands’ Solace subsidiary (see press release dated September 18, 2019) is authorized to market and sell their Pain Relief Roll-on as a natural health product through the Apothecary Naturals line of products. Licensed products have been assessed by Health Canada and found to be safe, effective and of high quality under their recommended conditions of use.

geyser
Live pain free for a more active life with Apothecary’s all natural Pain Roll-on. (CNW Group/Geyser Brands Inc.)

According to the Allied Market Research, the global topical pain relief market garnered $7.48 billion in 2017, and is expected to reach $13.28 billion by 2025, growing at a CAGR of 7.4% from 2018 to 2025. With distribution through traditional retailers and direct-to-consumer, products are expected to hit shelves in October, 2019.


The Solace subsidiary carries the Apothecary line of brands including:

“Receiving our NPN supports our vision to develop and build brands based on trust and credibility in an emerging but heavily regulated industry. Our continued focus on natural, healthy ingredients along with world-class formulations has been recognized with this NPN and we look forward to rolling these out in Canada as a first step in building a global presence”, stated Geyser Brands Chairman, Brad Kersch. “We have over 15,000 square feet of GMP-rated manufacturing space and our plans are to increase our capacity significantly in preparation for the next growth phase in the cannabis space”, he added.

Solace was also granted a Site License from Health Canada for its Coquitlam operations.  The site licence holder, indicates sites that have been authorized to manufacture, package, label and/or import natural health products by Health Canada.

About Geyser Brands

Geyser Brands develops consumer product brands that use hemp and CBD as a value-added ingredient. These involve next-generation formulas that focus on the mix of cannabinoids for specific conditions such as insomnia, anxiety and pain. Proprietary delivery technologies include all natural nano-technology, slow-release mechanisms and non-molecule degrading baking processes. In anticipation of coming edibles legislation, and with its Health Canada approved Licensed Production Facility, Geyser Brands has 15,000 sqft in two GMP facilities in Vancouver for edibles.

For more information, visit Geyser Brands’ website at www.geyserbrands.com.

On Behalf of the Board of Directors

“Andreas Thatcher”
Andreas Thatcher
Director and CEO
andreas@geyserinc.ca

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. Forward‐looking statements and information are often, but not always, identified by the use of words such as “appear”, “seek”, “anticipate”, “plan”, “continue”, “estimate”, “approximate”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe”, “would” and similar expressions.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with the marijuana industry in general such as operational risks in growing; competition; incorrect assessment of the value and potential benefits of various transactions; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and government regulations. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information relating to Geyser is available at www.sedar.com.

Click here to connect with Geyser Brands Inc. (TSXV:GYSR) for an Investor Presentation.

Source

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less